Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHN Achillion Pharmaceuticals	$6.76	$6.76	$2.06 ▼ $7.01	$946.72M	1.59	8.44 million shs	N/A
APLT Applied Therapeutics	$0.41 0.0%	$0.39	$0.30 ▼ $10.62	$58.60M	1.82	3.47 million shs	1.18 million shs
APRE Aprea Therapeutics	$1.73 -2.3%	$1.74	$1.41 ▼ $5.01	$9.57M	1.19	27,080 shs	62,917 shs
KNSA Kiniksa Pharmaceuticals International	$28.09 -3.0%	$27.72	$17.82 ▼ $30.69	$2.05B	0.05	555,944 shs	355,269 shs
PHAT Phathom Pharmaceuticals	$9.18 -5.3%	$6.79	$2.21 ▼ $19.71	$640.89M	0.45	1.55 million shs	768,804 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHN Achillion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+754.41%
APLT Applied Therapeutics	0.00%	+22.82%	+13.40%	+11.38%	-92.10%
APRE Aprea Therapeutics	0.00%	-1.14%	-9.90%	+11.61%	-56.20%
KNSA Kiniksa Pharmaceuticals International	0.00%	+0.84%	+1.30%	+45.47%	+34.02%
PHAT Phathom Pharmaceuticals	0.00%	+4.73%	-8.47%	+88.11%	-12.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APLT Applied Therapeutics	4.3426 of 5 stars	3.3	3.0	0.0	4.7	2.2	1.7	1.3
APRE Aprea Therapeutics	2.9245 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
KNSA Kiniksa Pharmaceuticals International	3.4055 of 5 stars	3.5	4.0	0.0	0.0	2.3	3.3	0.6
PHAT Phathom Pharmaceuticals	4.2219 of 5 stars	4.5	4.0	0.0	0.0	1.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHN Achillion Pharmaceuticals	0.00	N/A	N/A	N/A
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,373.79% Upside
APRE Aprea Therapeutics	3.00	Buy	$15.50	795.95% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	40.03% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	90.63% Upside

Current Analyst Ratings Breakdown

Latest KNSA, APRE, ACHN, PHAT, and APLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/21/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
APLT Applied Therapeutics	$265K	221.13	N/A	N/A	$0.49 per share	0.84
APRE Aprea Therapeutics	$1.50M	6.38	N/A	N/A	$3.55 per share	0.49
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.84	N/A	N/A	$6.60 per share	4.26
PHAT Phathom Pharmaceuticals	$81.86M	7.83	N/A	N/A	($3.71) per share	-2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHN Achillion Pharmaceuticals	-$70.27M	-$0.51	N/A	N/A	N/A	N/A	-30.95%	-29.09%	N/A
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	112.36	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)

Latest KNSA, APRE, ACHN, PHAT, and APLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
4/14/2025	Q4 2024	APLT Applied Therapeutics	-$0.18	-$0.24	-$0.06	$0.33	$0.61 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHN Achillion Pharmaceuticals	0.01	8.96	8.96
APLT Applied Therapeutics	N/A	3.00	3.00
APRE Aprea Therapeutics	N/A	5.90	5.90
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHN Achillion Pharmaceuticals	79.42%
APLT Applied Therapeutics	98.31%
APRE Aprea Therapeutics	34.19%
KNSA Kiniksa Pharmaceuticals International	53.95%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
ACHN Achillion Pharmaceuticals	4.58%
APLT Applied Therapeutics	1.60%
APRE Aprea Therapeutics	13.63%
KNSA Kiniksa Pharmaceuticals International	53.48%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHN Achillion Pharmaceuticals	56	140.05 million	N/A	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable

KNSA, APRE, ACHN, PHAT, and APLT Headlines

Recent News About These Companies

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from Brokerages

4 hours ago | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.4% - Here's What Happened

July 7, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's Why

July 1, 2025 | marketbeat.com

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

June 25, 2025 | seekingalpha.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - Morningstar

June 24, 2025 | morningstar.comM

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

June 23, 2025 | news.bloomberglaw.comN

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?

June 23, 2025 | marketbeat.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by Brokerages

June 18, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?

June 16, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16, 2025 | globenewswire.com

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

June 10, 2025 | seekingalpha.com

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long

June 9, 2025 | seekingalpha.com

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

June 9, 2025 | zacks.com

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

June 8, 2025 | finanznachrichten.de

Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock

June 7, 2025 | investing.com

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

June 6, 2025 | uk.finance.yahoo.com

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

June 6, 2025 | msn.com

Phathom surges 125% after FDA grants petition on Voquezna exclusivity

June 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA, APRE, ACHN, PHAT, and APLT Company Descriptions

Achillion Pharmaceuticals NASDAQ:ACHN

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Applied Therapeutics NASDAQ:APLT

$0.41 0.00 (-0.05%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.41 0.00 (-0.46%)

As of 07/11/2025 07:41 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Aprea Therapeutics NASDAQ:APRE

$1.73 -0.04 (-2.26%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$1.76 +0.03 (+1.73%)

As of 07/11/2025 07:07 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.09 -0.86 (-2.97%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$28.24 +0.15 (+0.52%)

As of 07/11/2025 08:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.18 -0.51 (-5.26%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.34 +0.16 (+1.69%)

As of 07/11/2025 05:39 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time